Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with new publications related to a specific clinical study. Additionally, several outdated dates and revision numbers have been removed.SummaryDifference5%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has been updated to include the term 'Merkel Cell Carcinoma' and a new identifier for the study, while significant details about the study's design and inclusion/exclusion criteria have been removed.SummaryDifference31%
- Check53 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed a date of March 25, 2025, while adding a new date of December 31, 2024.SummaryDifference0.5%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.